Influence of Exceptional Patient Characteristics on Everolimus Exposure

• Status: Completed
• Trial end date: 2018-01-15
• Target enrollment: 0
• Participant gender: Female

Summary

A study to determine whether everolimus pharmacokinetics in elderly and obese patients is different compared to control patients.

Furthermore the investigators will investigate the relation between metabolic response assessed with [18F] Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) and everolimus exposure and clinical benefit.

The investigators will explore whether dose escalation in patients who are hypothetically underexposed will result in an increase in metabolic response.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Radboud University
• Collaborator: Novartis
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

• Adult women (≥ 18 years of age) with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.

• Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer

• Postmenopausal women

• Radiological or clinical evidence of recurrence or progression on last systemic therapy prior to enrollment.

• Progression following a non-steroidal aromatase inhibitor

• Falling into one of the following categories

• elderly patients (age ≥ 70 years and BMI < 30 kg/m2); or

• obese patients (BMI ≥ 30 kg/m2 and age < 70 years); or

• control patients (BMI < 30 kg/m2 and age < 70 years);

• Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 x ULN

• Adequate renal function: calculated creatinine clearance, as estimated by GFR using the MDRD formula, is ≥ 30ml/min/1.73m2

• Performance status ECOG 0 - 2 (Karnofsky index: 60 - 100)

• Patient is willing and able to sign the Informed Consent Form prior to screening evaluations

Exclusion Criteria:

• Patients aged ≥ 70 years AND BMI ≥ 30 kg/m2

• HER2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive).

• Previous treatment with exemestane or mTOR inhibitors. Except for the treatment with exemestane in the adjuvant setting.

• Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin).

• Patients with a known history of HIV seropositivity.

• Any severe and / or uncontrolled medical conditions such as:

• Unstable angina pectoris, serious uncontrolled cardiac arrhythmia

• Patients with severe hepatic impairment (Child-Pugh A/B/C)

• Uncontrolled diabetes mellitus

• Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)

• Patients who test positive for hepatitis B or C

• Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A within the last 5 days prior to enrollment

• History of non-compliance to medical regimens

• Patients unwilling to or unable to comply with the protocol